Klaria Pharma Holding Quarterly Report Q1 2019

Encouraging progress in Klaria’s cannabinoid program

First three months of the year (January – March)

Net sales 3,8 MSEK (0,0 MSEK)

R&D costs for the period amounted to 4,8 MSEK (5,1 MSEK)

Net income for the period amounted to -2,1 MSEK (-6,2 MSEK)

Earnings per share amounted to -0,07 SEK (-0,20 SEK)

Cash flow from operations amounted to 0,8 MSEK (-3,7 MSEK)

Cash and cash equivalents on the balance day amounted to 8.7 MSEK (13.4 MSEK)

Shareholder’s equity per March 31, 2019 amounted to 92.6 MSEK (115.8 MSEK)